Strong economic growth and the prospect of declining interest rates continue to support gains in global equities.

Join us as we gather the world's top young leaders, founders and creators for four days of connecting, learning, teaching and building in our new host city of ...

More stable investment management and net interest income could cause investors to reassess Goldman's earnings quality and increase their willingness to pay a premium for it.

Goldman Sachs CEO David Solomon was awarded an $80 ... with the remainder in stock and a new type of incentive award. After graduating from college, Solomon was rejected by Goldman for ...

Bank of America Securities analyst Ebrahim Poonawala maintained a Buy rating on Goldman Sachs Group (GS – Research Report) today. The company’s ...

Technologies (NASDAQ: DVAX) fell 6% Tuesday after Goldman Sachs issued a rare "sell" rating on the biopharmaceutical company, ...

Millions of government workers have to decide whether to accept the new administration's resignation offer, but some are ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

AI investors are desperately trying to find clues on the real impact of DeepSeek on chip demand in the future and gauge how the breakthrough in China would impact US companies.

The start of 2025 could herald a new return to office push ... Other major employers, including JPMorgan and Goldman Sachs, have also abandoned the hybrid attendance policy they adopted during ...

Goldman Sachs analyst warns 340B reforms could ... as potential cost-saving measures by the new administration. Overall, for the 340B program, the analyst sees potential policy/legal outcomes ...

Goldman Sachs analyst Matthew Sykes double downgraded Cytek Biosciences (CTKB) to Sell from Buy with a price target of $4.50, down from $7. The ...